GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenerative Medical Technology Group Inc (OTCPK:RMTG) » Definitions » Net Change in Cash

RMTG (Regenerative Medical Technology Group) Net Change in Cash : $0.63 Mil (TTM As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Regenerative Medical Technology Group Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Regenerative Medical Technology Group's Net Change in Cash for the three months ended in Dec. 2024 was $0.33 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 was $0.63 Mil.

Regenerative Medical Technology Group Net Change in Cash Historical Data

The historical data trend for Regenerative Medical Technology Group's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenerative Medical Technology Group Net Change in Cash Chart

Regenerative Medical Technology Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Change in Cash
Get a 7-Day Free Trial 0.02 2.94 -1.33 -1.12 0.64

Regenerative Medical Technology Group Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.31 0.05 0.04 0.22 0.33

Regenerative Medical Technology Group Net Change in Cash Calculation

Regenerative Medical Technology Group's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=0.851+-0.215+0+0
=0.64

Regenerative Medical Technology Group's Net Change in Cash for the quarter that ended in Dec. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=0.379+-0.05+0+0
=0.33

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenerative Medical Technology Group Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Regenerative Medical Technology Group's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenerative Medical Technology Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenerative Medical Technology Group Inc (OTCPK:RMTG) » Definitions » Net Change in Cash
Comparable Companies
VRPX VINC CYTOF SCPX GSTC ENDV KRBPQ TSOI CNBX NBIO VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
433 Plaza Real, Suite 275, Boca Raton, FL, USA, 33432
Website
https://www.regenmedtechgroup.com
Regenerative Medical Technology Group Inc operates through its subsidiary. Its focus has been mainly dedicated to its operations serving the markets in the regenerative medicine industry. It believes stem cell therapy is becoming an increasingly effective clinical solution for treating conditions that traditional or conventional medicine only offers within palliative care and pain management. Patients around the world are seeking a natural regenerative alternative without the potential risks and side effects sometimes associated with conventional pharmaceuticals.
Executives
Benito Novas 10 percent owner 433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
David Eugene Christensen director, 10 percent owner, officer: President and CEO 433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
Pereira Melvin Antonio Loria director, 10 percent owner, officer: CEO, Chairman RESIDENCIAL HACIENDA EL GREGAL, #24-1 SANCHEZ, CURRIDABAT, SAN JOSE G2 11803